Back to Search Start Over

Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis

Authors :
Christian Jansen
Paolo Angeli
Manuela Merli
Francesco Salerno
Tania M. Welzel
Vicente Arroyo
Jonel Trebicka
Rita Garcia
Andrea De Gottardi
Agustín Albillos
Alex Amoros
Richard Moreau
Germán Soriano
Cristina Sanchez
Joan Clària
Alexander L. Gerbes
Fatima Aziz
Mireya Arteaga
François Durand
Elisabet Garcia
Daniela Campion
Thierry Gustot
Barbara Lattanzi
Verónica Prado
Filippo Morando
Victor Vargas
Marco Pavesi
Christophe Moreno
María Hernández-Tejero
Rafael Bañares
Henning Grønbæk
Rudolf E. Stauber
Niels Kristian Aagaard
Carlo Alessandria
Javier Fernández
Source :
Clinical gastroenterology and hepatology, 18 (4, Fernández, J, Angeli, P, Trebicka, J, Merli, M, Gustot, T, Alessandria, C, Aagaard, N K, de Gottardi, A, Welzel, T M, Gerbes, A, Soriano, G, Vargas, V, Albillos, A, Salerno, F, Durand, F, Bañares, R, Stauber, R, Prado, V, Arteaga, M, Hernández-Tejero, M, Aziz, F, Morando, F, Jansen, C, Lattanzi, B, Moreno, C, Campion, D, Gronbaek, H, Garcia, R, Sánchez, C, García, E, Amorós, A, Pavesi, M, Clària, J, Moreau, R & Arroyo, V 2020, ' Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis ', Clinical Gastroenterology and Hepatology, vol. 18, no. 4, pp. 963-973.e14 . https://doi.org/10.1016/j.cgh.2019.07.055, Dipòsit Digital de la UB, Universidad de Barcelona
Publication Year :
2019

Abstract

Background & Aims: We performed a randomized trial to determine whether albumin should be administered to patients with infections unrelated to spontaneous bacterial peritonitis (SBP). Methods: We performed a multicenter, open-label trial in which 118 patients with cirrhosis, non-SBP infections, and additional risk factors for poor outcome were randomly assigned to receive antibiotics plus albumin (study group; n = 61) or antibiotics alone (control group; n = 57). The primary outcome was in-hospital mortality; secondary outcomes were effect of albumin on disease course. Results: There were no significant differences at baseline between groups in results from standard laboratory tests, serum markers of inflammation, circulatory dysfunction, or liver severity scores. However, the combined prevalence of acute on chronic liver failure (ACLF) and kidney dysfunction was significantly higher in the study group (44.3% vs 24.6% in the control group; P = .02), indicating greater baseline overall severity. There was no significant difference in the primary outcome between groups (13.1% in the study group vs 10.5% in the control group; P = .66). Circulatory and renal functions improved in only the study group. A significantly higher proportion of patients in the study group had resolution of ACLF (82.3% vs 33.3% in the control group; P = .03). A significantly lower proportion of patients in the study group developed nosocomial infections (6.6% vs 24.6% in the control group; P = .007). Conclusions: In a randomized trial of patients with advanced cirrhosis and non-SBP infections, in-hospital mortality was similar between those who received albumin plus antibiotics vs those who received only antibiotics (controls). However, patients given albumin were sicker at baseline and, during the follow-up period, a higher proportion had ACLF resolution and a lower proportion had nosocomial infections. ClinicalTrials.gov no: NCT02034279.<br />SCOPUS: ar.j<br />info:eu-repo/semantics/published

Details

ISSN :
15427714
Volume :
18
Issue :
4
Database :
OpenAIRE
Journal :
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Accession number :
edsair.doi.dedup.....829e0529f3e51526e4af016ca2bbf0b4